483
TakedaTakeda – FDA 483, Sep 25, 2019
Record Details
An FDA inspection of Takeda's biologic drug manufacturing facility in Round Lake, IL, revealed significant deficiencies. The firm was cited for failing to minimize contamination risk during albumin bulk filling operations, evidenced by microbial exceedances. Additionally, Takeda's corrective actions were deemed ineffective in addressing recurring issues with leaking product bags, and the company failed to complete its required annual drug establishment registration.
View Company Profile
ID · 24d6b334-0b96-4884-8662-276eba08e27b
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.